A temporal trend analysis of breast and prostate cancer mortality rates in Lithuania, 1986-2020 | BMC Public Health
Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–87.
Wojtyla C, Bertuccio P, Wojtyla A, La Vecchia C. European trends in breast cancer mortality, 1980-2017 and forecasts to 2025. Eur J Cancer. 2021;152:4–17.
Bertuccio P, Santucci C, Carioli G, Malvezzi M, La Vecchia C, Negri E. Trends in mortality from urological cancers in Europe over the period 1980-2017 and projection until 2025. Eur Urol Oncol. 2021;4(5):677–96.
Sebuødegård S, Botteri E, Hofvind S. Breast cancer mortality after the implementation of population-based organized breast cancer screening in Norway. J Natl Cancer Institute 2020; 112(8): 839–846. Erratum in: J Natl Cancer Inst 2020;112(10):1072–4.
Carioli G, Malvezzi M, Rodriguez T, Bertuccio P, Negri E, La Vecchia C. Trends and forecasts until 2020 of breast cancer mortality in Europe. Breast. 2017;36:89–95.
Kvåle R, Myklebust TA, Engholm G, Heinävaara S, Wist E, Møller B. Prostate and breast cancer in four Nordic countries: a comparison of incidence and mortality trends across countries and groups age 1975-2013. Int J Cancer. 2017;141:2228–42.
López-Abente G, Mispireta S, Pollán M. Breast and prostate cancer: analysis of common epidemiological characteristics of mortality trends in Spain. BMC Cancer. 2014;14:874.
Welch HG, Albertsen PC. Reconsidering prostate cancer mortality – the future of PSA screening. N Engl J Med. 2020;382(16):1557–63.
Dyba T, Randi G, Bray F, Martos C, Giusti F, Nicholson N, et al. The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer. 2021;157:308–47.
Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global trends in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38–52.
Gondos A, Krilaviciute A, Smailyte G, Ulys A, Brenner H. Cancer surveillance using registry data: results and recommendations for the Lithuanian national program for early detection of prostate cancer. Eur J Cancer. 2015;51(12):1630–7.
Lopez-Otin C, Diamandis EP. Breast and prostate cancer: an analysis of common epidemiological, genetic and biochemical characteristics. Endocr Rev. 1998;19(4):365–96.
National Health Insurance Fund under the Ministry of Health of Lithuania. Performance of the breast cancer screening program in Lithuania in 2019. Available at: https://ligoniukasa.lrv.lt/uploads/ligoniukasa/documents/files/Veiklos_sritys/Ligu_prevencijos_programos/0324%202019%20patikros%20d%C4%97l %20kr%20v %C4%97%C5%BEio%20atask.pdf. Accessed January 18, 2022. in Lithuanian.
Ponti A, Anttila A, Ronco G, Senore C, Basu P, Segnan N, Tomatis M, Žakelj MP, Dillner J, Fernan M, Elfström KM, Lönnberg S, Soerjomataram I, Vale D. Cancer screening in the European Union . Report on the implementation of the Council recommendation on cancer screening. Lyon: International Agency for Research on Cancer, 2017. 313.
Zhou CK, Check DP, Lortet-Tieulent J, Laversanne M, Jemal A, Ferlay J, et al. Incidence of prostate cancer in 43 world populations: an analysis of global and age-group temporal trends. Int J Cancer. 2016;138:1388–400.
Innos K, Baburin A, Kotsar A, Eiche IE, Lang K. Prostate cancer incidence, mortality and survival trends in Estonia, 1995-2014. Scand J Urol. 2017;51(6):442–9.
Hugosson J, Roobol MJ, Månsson M, Tammela TLJ, Zappa M, Nelen V, et al. A 16-year follow-up of the European Randomized Prostate Cancer Screening Study. Eur Urol. 2019;76:43–51.
Van Poppel H, Roobol MJ, Chapple CR, Catto JWF, N’Dow J, Sønksen J, et al. Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: position and recommendations of the European Urological Association for 2021. Eur Urol. 2021;80(6):703–11.
Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. Screening for prostate cancer with the prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018;5(362):k3519. https://doi.org/10.1136/bmj.k3519.
EU Council Recommendation on cancer screening of 2 December 2003. (2003/878/EC). Official Journal of the European Union 16.12.2003. https://ec.europa.eu/jrc/sites/default/files/2_December_2003%20cancer%20screening.pdf. Accessed October 26, 2021.
Mottet N, Cornford P, van den Bergh RCN, Briers E, De Santis M, Gillessen S, Grummet J, Henry A. M, van der Kwast TH, Lam TB, Mason MD, O’Hanlon S, Oprea-Lager DE, Ploussard G, van der Poel HG, Rouvière O, Schoots IG, Tilki D, Wiegel T, Van den Broeck T, Cumberbatch M, Farolfi A, Fossati N, Gandaglia G, Grivas N, Lardas M, Liew M, Moris L, Willemse PP.M. EAU-EANM-ESTRO-ESUR-ISUP-SIOG recommendations on prostate cancer. Arnhem, The Netherlands: European Association of Urology, 2021. https://uroweb.org/wp-content/uploads/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2021V3. pdf. Accessed January 18, 2022.
Van Poppel H, Hogenhout R, Albers P, van den Bergh RCN, Barentsz JO, Roobol MJ. A European model for an organized risk-stratified early detection program for prostate cancer. Eur Urol Oncol. 2021;4(5):731–9.
European code against cancer. International Agency for Research on Cancer. https://cancer-code-europe.iarc.fr/index.php/en/ecac-12-ways. Accessed January 18, 2022.
Eklund M, Jäderling F, Discacciati A, Bergman M, Annerstedt M, Aly M, et al. STHLM3 Consortium. Targeted or standard biopsy by MRI in the context of prostate cancer screening. N Engl J Med. 2021;385(10):908–20.
National Health Insurance Fund under the Ministry of Health of Lithuania. Performance of the prostate cancer screening program in Lithuania in 2019. Available at: https://ligoniukasa.lrv.lt/uploads/ligoniukasa/documents/files/Veiklos_sritys/Ligu_prevencijos_programos/2019%20m_%20prie%C5%A1in% C4%97s%20liaukos%20v%C4%97%C5%BEio%20ankstyvosios%20diagnostikos%20programos%20ataskaita.pdf. Accessed January 18, 2022. in Lithuanian.
Everatt R, Kuzmickienė I, Intaitė B, Anttila A. Effectiveness of cervical cancer prevention program: a case-control audit of mortality in Lithuania. Eur J Cancer Prev. 2020;29(6):504–10.
World Health Organization (WHO) database. https://www.who.int/data/data-collection-tools/who-mortality-database. Accessed March 24, 2022.
Statistics Lithuania. https://osp.stat.gov.lt/statistiniu-rodikliu-analize#/. Accessed January 18, 2022.
National Cancer Institute, Joinpoint Regression Program Version 126.96.36.199, June: National Cancer Institute, Bethesda (MD), 2017. https://surveillance.cancer.gov/joinpoint/.
Rosenberg PS, Check DP, Anderson WF. A web-based tool for age-period-cohort analysis of cancer incidence and mortality rates. Cancer Epidemiol Biomark Prev 2014;23(11):2296–2302. https://doi.org/10.1158/1055-9965.EPI-14-0300.
Autier P, Boniol M, La Vecchia C, Vatten L, Gavin A, Héry C, et al. Disparities in breast cancer mortality trends between 30 European countries: retrospective analysis of trends from the WHO Mortality Database. BMJ. 2010;341:c3620.
Malvezzi M, Carioli G, Bertuccio P, Negri E, La Vecchia C. Relationship between trends in mortality from cardiovascular diseases and certain cancers in the European Union, in 1970-2017. Focus on cohort and period effects. Eur J Cancer. 2018;103:341–55.
Grabauskas V, Klumbienė J, Petkevičienė J, Šakytė E, Kriaučionienė V, Veryga V. Health behavior among Lithuanian adult population, 2014. Kaunas: Lithuanian University of Health Sciences, 2015. 146.
Grabauskas V, Klumbienė J, Petkevičienė J, Dregval L. Čepaitis Ž, Nedzelskienė I, Puska P, Uutela A, Helakorpi S. Health behavior among Lithuanian adult population, 1994. Kaunas Medical Academy, Lithuania. Helsinki: National Institute of Public Health, 1997.
The World Bank Group, 2022. https://data.worldbank.org/indicator/SP.DYN.CONU.ZS?locations=LT. Accessed January 20, 2022.
Steponaviciene L, Briediene R, Vanseviciute R, Smailyte G. Trends in breast cancer incidence and stage distribution before and during introduction of mammography screening program in Lithuania. Fight against cancer. 2019;26(1):1073274818821096. https://doi.org/10.1177/1073274818821096.
Duggan C, Trapani D, Ilbawi AM, Fidarova E, Laversanne M, Curigliano G, et al. National health system characteristics, stage of breast cancer at diagnosis, and breast cancer mortality: a population-based analysis. Lancet Oncol. 2021;22(11):1632–42. https://doi.org/10.1016/S1470-2045(21)00462-9.
Héry C, Ferlay J, Boniol M, Autier P. Quantification of changes in breast cancer incidence and mortality since 1990 in 35 predominantly Caucasian countries. Anne Oncol. 2008;19(6):1187–94.
Adliene D, Adlys G, Cerapaite R, Jonaitiene E, Cibulskaite I. Optimization of radiographic examinations in Lithuania: start of implementation in mammography. Radiat Prot Dosim. 2005;114(1–3):399–402. https://doi.org/10.1093/rpd/nch520.
Grabauskas VJ, Klumbienė J, Petkevičienė J, Katvickis A, Šačkutė A, Helasoja V, et al. Prättälä Ritva. Health behavior among Lithuanian adult population, 2004. Helsinki: National Institute of Public Health; 2005. p. 164.
Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61(6):1079–92.
Feuer EJ, Merrill RM, Hankey BF. Cancer Surveillance Series: Interpreting Prostate Cancer Trends – Part II: Misclassification of Causes of Death and Recent Rise and Fall in Prostate Cancer Mortality. J Natl Cancer Inst. 1999;91(12):1025–1032.
Patasius A, Krilaviciute A, Smailyte G. Screening for prostate cancer with PSA: ten years of experience from the population-based prostate cancer early detection program in Lithuania. J Clin Med. 2020;9(12):3826.
Seikkula HA, Kaipia AJ, Ryynänen H, Seppä K, Pitkäniemi JM, Malila NK, et al. The impact of socioeconomic status on stage-specific prostate cancer survival and mortality before and after the introduction of PSA testing in Finland. Int J Cancer. 2018;142(5):891–8.
Shoag JE, Nyame YA, Gulati R, Etzioni R, Hu JC. Reconsidering the trade-offs of prostate cancer screening. N Engl J Med. 2020;382(25):2465–8.